Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
UBS
Farmers Insurance
Novartis
Cipla
US Department of Justice
Daiichi Sankyo
Johnson and Johnson
Dow
Harvard Business School

Generated: August 17, 2017

DrugPatentWatch Database Preview

Valeant Bermuda Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT BERMUDA, and when can generic versions of VALEANT BERMUDA drugs launch?

VALEANT BERMUDA has eight approved drugs.

There are five US patents protecting VALEANT BERMUDA drugs.

There are eighty-eight patent family members on VALEANT BERMUDA drugs in thirty-six countries.

Summary for Applicant: Valeant Bermuda

Patents:5
Tradenames:7
Ingredients:7
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Bermuda
ELIDEL
pimecrolimus
CREAM;TOPICAL021302-001Dec 13, 2001RXYesYes► Subscribe► Subscribe ► Subscribe
Valeant Bermuda
ZOVIRAX
acyclovir
OINTMENT;TOPICAL018604-001Mar 29, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL019049-001Sep 16, 1988ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982AB1RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Bermuda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant Bermuda
ELIDEL
pimecrolimus
CREAM;TOPICAL021302-001Dec 13, 2001► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009► Subscribe► Subscribe
Valeant Bermuda
PENLAC
ciclopirox
SOLUTION;TOPICAL021022-001Dec 17, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Valeant Bermuda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,337,324 Pharmaceutical combination► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Bermuda Drugs

Country Document Number Estimated Expiration
Norway983402► Subscribe
CroatiaP960034► Subscribe
Spain2199339► Subscribe
Algeria1966► Subscribe
Germany69632034► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Bermuda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013025Lithuania► SubscribePRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C/GB05/029United Kingdom► SubscribePRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218
C/GB10/005United Kingdom► SubscribePRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
/2001Austria► SubscribePRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
00097Netherlands► SubscribePRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
McKesson
Julphar
Boehringer Ingelheim
Moodys
Argus Health
Citi
Novartis
AstraZeneca
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot